ImmuPharma CEO Tim McCarthy shares latest developments with P140 platform, road ahead

(13:6)

Stock Surge: GreenPower and ImmuPharma Lead the Charge in Market Gains

(3:10)

ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments

(22:35)

ImmuPharma expects new Lupozor study to begin in H2 2023

(8:49)

ImmuPharma \

(11:39)

ImmuPharma: Equity analyst eyes key FDA decision in August

(7:13)

ImmuPharma CEO still open to big pharma deal

(6:6)

Immupharma chairman 'delighted' with first significant investment from specialist US funds

(12:27)

Immupharma 'looking forward and planning for success' with Lupuzor

(7:41)

ImmuPharma confident of topline results from Phase III Lupuzor trial this quarter

(8:43)

ImmuPharma \

(12:49)

ImmuPharma's Dimitriou explains opportunities for Nucant

(4:37)

ImmuPharma \

(10:6)

ImmuPharma PLC to open Lupuzor trial site in Mauritius

(6:8)

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' Lupuzor licensing deal

(8:51)

ImmuPharma’s McCarthy on phase III Lupuzor trials

(4:35)

Dimitri Dimitriou on Lupuzor | Immupharma | The New Economy Videos

(7:32)

ImmuPharma may broaden its collaboration with US partner Avion

(7:44)

ImmuPharma chair hails “successful” recruitment for Lupuzor trials

(6:53)

ImmuPharma presents plans for pharmacokinetic by the end of the current quarter

(7:33)